Bausch+Lomb announced today that an affiliate acquired Elios Vision,developer of a minimally invasive glaucoma surgery(MIGS)procedure.

博士倫公司今天宣布，其子公司收購了微創(chuàng)青光眼手術（MIGS）開發(fā)商Elios Vision公司。

The Elios procedure uses an excimer laser to treat glaucoma in conjunction with cataract surgery without implants.Bausch+Lomb believes the deal enhances its glaucoma portfolio which already features pharmaceutical and surgical approaches.

Elios手術使用準分子激光治療青光眼，同時進行白內障手術，無需植入人工晶體。博士倫認為，這項交易增強了其青光眼產(chǎn)品組合，該產(chǎn)品組合已包括藥物和手術方法。

Compared to other glaucoma surgery techniques,MIGS offers a safe and effective approach to lowering intraocular pressure.It also features a faster recovery time,according to a news release.Elios’version offers a tissue-friendly,precision,non-thermal laser-based and highly adoptable procedure for the treatment of glaucoma.The company currently offers the CE-marked technology in Europe and is pursuing FDA approval.

與其他青光眼手術技術相比，MIGS是一種安全有效的降低眼壓的方法。據(jù)一份新聞稿稱，它還具有恢復時間更短的特點。Elios公司的版本為青光眼治療提供了一種組織友好、精確、基于非熱激光且高度可采用的手術方法。該公司目前在歐洲提供獲得CE認證的技術，并正在申請美國食品和藥物管理局的批準。

Former Elios Chair and CEO Elliot Friedman said the companies aim to make combining cataract and glaucoma treatment the new standard of care.Friedman said the global presence of Bausch+Lomb makes that“even more attainable.”

艾里奧斯公司前董事長兼首席執(zhí)行官埃利奧特-弗里德曼（Elliot Friedman）說，兩家公司的目標是使白內障和青光眼的聯(lián)合治療成為新的治療標準。弗里德曼說，博士倫的全球業(yè)務使這一目標“更容易實現(xiàn)”。

“Today’s announcement further demonstrates our commitment to investing in smart,innovative technologies that enable eye care professionals to better address the evolving needs of their patients,”said Luc Bonnefoy,president,Surgical,Bausch+Lomb.“The ELIOS system offers a differentiated approach for the treatment of glaucoma,a condition expected to increase in prevalence by 47%from 2020 to 2040.”

“博士倫公司手術部總裁Luc Bonnefoy說："今天的聲明進一步證明了我們投資于智能創(chuàng)新技術的承諾，這些技術使眼科護理專業(yè)人員能夠更好地滿足患者不斷變化的需求。“ELIOS系統(tǒng)為治療青光眼提供了一種與眾不同的方法，預計從2020年到2040年，青光眼的發(fā)病率將增加47%。